26F1
Pre-clinical- Indications
- Parkinson's disease, Multiple system atrophy
Company intelligence / Profile preview
Syngle Therapeutics
Randstad, Netherlandssyngletherapeutics.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
Syngle Therapeutics is developing antibodies against oligomeric alphasynuclein for Parkinson's disease treatment. Their lead candidate 26F1 is currently in preclinical development.
- Therapeutic areas
- Neurology
- Modalities
- AntibodyImmunotherapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Crossbeta Biosciences
Beyond the preview
Go deeper on Syngle Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Syngle Therapeutics.